Key result
Non-ischemic cardiomyopathy was associated with significantly lower all-cause mortality after cardiac resynchronization therapy compared to ischemic cardiomyopathy (RR 1.37; 95% CI 1.16-1.61).
Why the study?
To compare long-term clinical outcomes between heart failure patients with non-ischemic cardiomyopathy versus ischemic cardiomyopathy after cardiac resynchronization therapy.
Does non-ischemic cardiomyopathy etiology improve all-cause mortality and reverse remodeling compared to ischemic cardiomyopathy in heart failure patients receiving cardiac resynchronization therapy?
Meta-Analysis (n=12,331)
Does non-ischemic cardiomyopathy etiology improve all-cause mortality and reverse remodeling compared to ischemic cardiomyopathy in heart failure patients receiving cardiac resynchronization therapy?
Relative Risk: 1.37 (95% CI 1.16–1.61)
In patients receiving cardiac resynchronization therapy, non-ischemic etiology is associated with significantly lower all-cause mortality and greater left ventricular reverse remodeling compared to ischemic etiology.
No takes yet. Share an insight, caveat, or question.
Non-ischemic etiology may confer better CRT prognosis; leaves open whether randomized trials should test etiology-specific strategies.
Chen et al. (2018) conducted a meta-analysis in Heart failure (n=12,331). Non-ischemic cardiomyopathy (NICM) vs. Ischemic cardiomyopathy (ICM) was evaluated on All-cause mortality (RR 1.37, 95% CI 1.16-1.61). Non-ischemic cardiomyopathy was associated with significantly lower all-cause mortality after cardiac resynchronization therapy compared to ischemic cardiomyopathy (RR 1.37; 95% CI 1.16-1.61).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: